title: Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans.
abstract: Bisphosphonates have been shown to decrease bone turnover in a variety of high turnover states. We postulated that pamidronate (APD), a bisphosphonate, could prevent the increased bone turnover caused by thyroid hormone excess. Twenty-two male subjects were randomized to receive either placebo (group 1) or APD (30 mg, iv, daily for 2 days; group 2). Subsequently, all subjects received T3 (50 micrograms, twice daily, for 8 days). Biochemical indices of bone turnover were measured in blood and urine at baseline, after treatment with APD/placebo, and after treatment with T3. The urinary calcium/creatinine ratio (Uca/cr) fell significantly after treatment with APD, but not after treatment with placebo (group 1, 0.131 +/- 0.021; group 2, 0.040 +/- 0.013 mmol Ca/mmol Cr; P < 0.002). After treatment with T3, Uca/cr rose significantly in group 1, but not in group 2 (group 1, 0.275 +/- 0.042; group 2, 0.065 +/- 0.025 mmol Ca/mmol Cr; P < 0.05). Thus, APD prevented the rise in Uca/cr caused by treatment with T3. Similar results were obtained with urinary hydroxyproline and urinary pyridinoline cross-links. We conclude that 8 days of mild thyroid hormone excess in normal men increases bone turnover, and prior administration of APD prevents thyroid hormone-induced increases in bone resorption. APD may be useful in the prevention of thyroid hormone-induced osteopenia.
authors.affiliation: Charles A. Dana Research Institute, Harvard-Thorndike Laboratory, Beth Israel Hospital, Boston, Massachusetts 02215.
authors.forename: H N
authors.initials: HN
authors.lastname: Rosen
authors.forename: A C
authors.initials: AC
authors.lastname: Moses
authors.forename: C
authors.initials: C
authors.lastname: Gundberg
authors.forename: V T
authors.initials: VT
authors.lastname: Kung
authors.forename: S M
authors.initials: SM
authors.lastname: Seyedin
authors.forename: T
authors.initials: T
authors.lastname: Chen
authors.forename: M
authors.initials: M
authors.lastname: Holick
authors.forename: S L
authors.initials: SL
authors.lastname: Greenspan
mesh_terms: D000293:Adolescent; D000328:Adult; D000596:Amino Acids / Q000652:urine; D001862:Bone Resorption / Q000139:chemically induced / Q000517:prevention & control*; D002117:Calcitriol / Q000097:blood; D002118:Calcium / Q000652:urine; D003404:Creatinine / Q000652:urine; D004164:Diphosphonates / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D007262:Infusions, Intravenous; D008297:Male; D015675:Osteocalcin / Q000097:blood; D000077268:Pamidronate; D010281:Parathyroid Hormone / Q000097:blood; D014284:Triiodothyronine
chemical_list: D000596:Amino Acids; D004164:Diphosphonates; D010281:Parathyroid Hormone; D014284:Triiodothyronine; D015675:Osteocalcin; C015484:pyridinoline; D003404:Creatinine; D002117:Calcitriol; D000077268:Pamidronate; D006909:Hydroxyproline; D002118:Calcium